JPH08198758A - Usage of glycogen as cancer-preventing agent - Google Patents

Abstract

PURPOSE: To obtain a cancer-preventing agent containing glycogen as a main ingredient and capable of naturally preventing carcinogenesis in an usual food life without taking a special medicine. CONSTITUTION: The cancer-preventing agent contains glycogen as a main ingredient. The glycogen is preferably a vital specimen containing glycogen, or glycogen obtained by extracting the specimen with hot water, treating the extract with a protease to remove protein parts, precipitating the left polysaccharide parts with an alcohol, and further purifying the precipitates with a weak ion exchange resin, etc. The glycogen is preferably taken in the form of capsules or tablets. The glycogen is usually administered at a dose of 0.4-1g per week for an adult.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of glycogen as a cancer preventive agent for preventing carcinogenesis by suppressing the occurrence of cancer.

[0002]

2. Description of the Related Art Even with medical technology, which is highly developed in the present age, cancer is not the top cause of death in Japan. Under such circumstances, methods of treating cancer include surgery or chemotherapy using a drug. Since the development of drugs used for chemotherapy is mainly those that suppress the growth of cancer cells or have the effect of necrosis, their serious side effects cannot be ignored. Not only that, neither of the therapies is applicable to all cancers, and it is hard to say that it is a reliable treatment method without early detection and early treatment.

[0003] As described above, in the present day when no definitive method or drug for cancer treatment has been found, prevention of cancer has been highlighted, and development of such a method is the greatest concern of human beings. That is, cancer is generally a three-stage theory that cells that become the origin of cancer are generated by the initiator, the cells increase by the promoter, and finally develop as cancer, but as in the current situation, it develops as cancer. Attempts have been made to prevent the cancer itself by inhibiting the initiator or promoter, rather than treating it by the method described above.

Although many studies have been conducted on substances capable of preventing cancer, in any case, many of them must be taken in consideration of cancer. Therefore, ingestion for a long period of time is accompanied by mental distress of the ingestion action itself, which requires great patience of the ingesting individual. On the other hand, if cancer prevention is not done by ingesting a special drug but is done naturally in the normal diet, it becomes possible to prevent cancer without being aware of it, and as a result It will no longer be a dream, and it will not be a dream to eradicate cancer from this world.

[0005]

Therefore, it has been desired to develop a method for suppressing the occurrence of cancer and preventing carcinogenesis by naturally ingesting foods or substances obtained from foods.

[0006]

[Means for Solving the Problems] In order to solve the above-mentioned problems, the inventors of the present invention have sought a substance that suppresses carcinogenic action in foods, and as a result of diligent research thereof, glycogen has a carcinogenic inhibitory activity. I found a thing.

That is, the present invention is disclosed in Japanese Patent Laid-Open No. 6-
When glycogen extracted by the method disclosed in 279292 was intraperitoneally administered to mice, the production of precancerous cells and the development of cancer were successfully suppressed with a significant difference. This means that the glycogen is considered to be effective for cancer prevention, and the present invention has been achieved. The present invention will be described in more detail below.

The cricogen used in the present invention is as disclosed in Japanese Patent Laid-Open No. 6-279292.
Glycogen or gel filtration obtained by precipitating a polysaccharide component using alcohol after removing a protein part by allowing a protease to act on the biological sample containing glycogen extracted with hot water or the biological sample as it is It means glycogen obtained by performing a separation operation such as.

It is more preferable to use glycogen which can be obtained by removing other polysaccharide components mixed in a trace amount by using a weak ion exchange resin or the like.

Glycogen obtained by this method is obtained in a state very close to the state in vivo as compared with glycogen obtained by the conventional extraction method using an acid or alkali or an organic solvent such as dimethyl sulfoxide. It is considered that the present invention exhibits properties similar to those of the previously filed invention and the present invention.

As the method for preventing cancer using the present glycogen, since glycogen is water-soluble, it can be administered by any method such as oral administration and intravenous injection.

In this case, the present glycogen may be inactivated under conditions such as acid, alkali, or precipitation-degrading enzyme. Therefore, the present glycogen is encapsulated in a capsule,
Alternatively, it is desirable to ingest in the form of tablets prepared by using a pharmaceutical carrier that can be appropriately decomposed by gastric juice or the like.

It is also possible to ingest a food containing glycogen by appropriately cooking, processing, or molding.

The dose of glycogen of the present invention is as follows:
Although it depends on the age of the patient, the body weight, the purpose of administration, and the degree of the disease, it is expected that the effect is usually from 0.4 g to 1 g per week in adults. However, the invention is in no way limited by this example.

Next, the present invention will be described in more detail by showing examples of administration of glycogen of the present invention.

(1) Animal Experiment The animals used in the experiment were male C3H / He mice and female C5.
The B6C3F1 mice obtained by mating 7BL / 6 mice were divided into males and females at 2 weeks after birth, and diethyl nitrosamine (DEN) was intraperitoneally administered to each mouse at 1 per kg body weight.
What administered 0 mg was used.

(2) Administration Experiment One week after the administration of DEN, glycogen was dissolved weekly in adjusted saline and intraperitoneally administered to mice. Experiments were carried out on a total of 3 test groups, each group receiving 200 μg per animal, a group administering 400 μg and only physiological saline.

(3) Test with Glutathione S-Transferase (GST-II) Antibody Twelve weeks after administration of DNE, mice were sacrificed by ether anesthesia and the liver was excised. After fixing the excised liver with acetone, a tissue section was prepared, and Hatayama et al., Biochemical and Biophysical Research Communications, 140, pp. 581-588 (198).
6 year), using the GST-II antibody prepared by the method shown in (6), the avidin-biotin-peroxidase method (A
Immunohistochemistry test was performed by the BC method).

The number of GST-II positive single cells considered to be origin cells in the immunochemically stained tissues was measured and the glycogen-administered group and non-administered group were compared. The results are shown in Table 1.

[0020]

[Table 1]

As is clear from the above results, it was confirmed that the group to which the glycogen of the present invention was administered at 200 μg and 400 significantly suppressed the generation of cells that could become cancer cells in the future, as compared with the control group. It was Therefore, the drug of the present invention is considered to be useful as a carcinogenesis preventive agent at an extremely early stage.

(4) Number of adenomas produced and c-Jun
Test by antibody A male mouse 6 months after DEN administration and a female mouse 10 months after DEN administration were sacrificed by ether anesthesia, and the liver was excised. The number and diameter of adenomas composed of precancerous cells in the removed liver were measured. After further fixing the excised liver with acetone, a tissue section was prepared, and C-J
An immunohistochemical test was carried out by the adivin-biotin-peroxidase method (ABC method) using the un antibody (manufactured by Oncogene Science).

The numbers and diameters of adenomas representing the precancerous state in the glycogen-administered group and the non-administered group were compared. The results are shown in Table 2.

[0024]

[Table 2]

From the above results, it was confirmed that the groups to which the glycogen of the present invention was administered at 200 μg and 400 μg suppressed the production of precancerous adenomas as compared with the control group. Therefore, the agent of the present invention is considered to be useful as a carcinogenic preventive agent at the stage of generating cells of precancerous bandage.

[0026] The number of cells and the area thereof showing positive for the antibody of c-Jun which is a marker of the enzyme mutation site in the glycogen administration group and the non-administration group were compared. Table 3 shows the results.

[0027]

[Table 3]

From the above results, the number of male mouse positive foci in the groups administered with glycogen of the present invention at 200 μg and 400 μg was also compared with the control group by immunohistochemistry of c-Jun antibody which is a marker of enzyme nest. And the area occupied by the liver showed a marked decrease in the glycogen-administered group. Even in male mice, cJ in the glycogen-administered group
A marked decrease in the area occupied by unpositive cells was observed. These results indicate that the glycogen of the present invention suppresses liver chemical carcinogenesis in mice.

[Short description of table]

[Table 1] Effect of Glycogen on GST-II Positive Cell Appearance in Female Mouse Liver G- thought to be a cancer-initiating cell in the liver of a 12-week-old female mouse administered with tylylnitrosamine (DEN).
The number of ST-II positive single cells was 75% in the 200 μg glycogen-administered group as compared with the glycogen-unadministered group, and 40
It decreased to 46% in the 0 μg administration group.

[Table 2] Inhibitory effect of glycogen on the induction of precancerous lesions in mouse liver In the liver of male mice 6 months after DEN administration, the number of adenomas was significantly decreased in the glycogen-administered group as compared to the glycogen-unadministered group. Similarly, DEN administration 10
In female mice aged 3 months, glycogen administration reduced the number of adenomas in half.

[Table 3] Inhibitory effect of glycogen on mouse c-Jun positive cell expression c-Ju, a marker of oxygen mutant foci
The immunohistochemistry of n also showed a marked decrease in the number of c-Jun positive foci and the area occupied in the liver of the male mouse in the glycogen administration group. A marked decrease in the area occupied by c-Jun positivity was observed in both female mice and the glycogen-administered group.

 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Matsue Hajime Aomori City, Aomori City, 8th character, Ashiya 202-4 Aomori Industrial Technology Development Center (72) Inventor Hidetaka Ichinohe Aomori City, Aomori Nishida Okitsu 257- 10 Aomori Tomouchi Co., Ltd. (72) Inventor Ichiro Hatayama 1-1, Higashi Zodo, Aomori City, Aomori Prefecture Aomori Environmental Health Center (72) Inventor, Keinori Miura 1-1, Higashi Zodo, Aomori City, Aomori Prefecture Aomori Prefectural Environmental Health Center (72) Inventor Junko Kimura 1-1 Azumamori Road, Aomori City, Aomori Prefecture Aomori Prefectural Environmental Health Center

Claims (1)

[Claims] 1. A preventive agent for cancer, which comprises glycogen as a main component.